Background-Our objectives were to identify correlates of mortality and congestive heart failure after aortic valve replacement (AVR) according to preoperative left ventricular (LV) function and to describe the incidence, time course, and correlates of LV recovery and mass regression postoperatively. Methods and Results-A total of 3112 patients with AVR were assessed in a follow-up clinic with echocardiography (median follow-up, 6.0 years). At operation, their mean age was 67.8±13.4 years, one third were female, and 29% had LV dysfunction (ejection fraction <50%). In severe patients with severe aortic stenosis and LV dysfunction, transaortic valve mean pressure gradient <40 mm Hg, longer cardiopulmonary bypass duration, and prosthesis-patient mismatch (indexed effective orifice area ≤0.85 cm 2 /m 2 ) were independent correlates of the composite outcome of death or congestive heart failure after AVR. In patients with severe aortic regurgitation and LV dysfunction, older age and higher preoperative LV mass were identified. LV recovery correlated with better survival and freedom from heart failure in patients with aortic stenosis. Maximum LV mass regression took 24 months in patients with aortic stenosis and nearly 5 years with aortic regurgitation; independent correlates included smaller LV end-systolic diameter in patients with aortic stenosis and low New York Heart Association class with aortic regurgitation. Conclusions-Incomplete LV recovery, prosthesis-patient mismatch, low transaortic valve pressure gradient, and higher LV mass are associated with increased mortality or heart failure after AVR in patients with LV dysfunction. Higher LV end-systolic diameter and symptoms correlate with less LV mass regression, which takes at least 2 years. These findings help surgeons and cardiologists refine the indications, timing, prognostication, and follow-up of patients before and after AVR. (Circulation. 2015;132:741-747.
A ortic valve replacement (AVR) is the most effective way to treat heart failure and to prevent death in patients with severe aortic valve disease, particularly symptomatic aortic stenosis (AS). 1, 2 The outcomes of AVR have improved over the last decade, 1 but the incidence and mortality of congestive heart failure (CHF) after AVR remain high among patients with left ventricular (LV) dysfunction. [3] [4] [5] One possible mechanism is nonrecovery of LV dysfunction after AVR. Because LV function affects clinical outcomes, 3, 6 incomplete LV recovery postoperatively may translate into decreased survival and quality of life. Usually, LV function worsens with long-standing pressure or volume overload and recovers after AVR with relief of this overload. 7 However, when scar or irreversible myocardial fibrosis has developed, postoperative mortality is higher and LV function is less likely to recover. 8, 9 Magnetic resonance imaging and dobutamine stress echocardiography can detect the amount of myocardial fibrosis and characterize low-gradient AS, respectively, but are not routinely performed because they do not often alter treatment decisions. 10 So far, no large series has identified the correlates of freedom from CHF and of LV function recovery after AVR in patients with LV dysfunction or LV hypertrophy (LVH). Here, we examine the impact of LV function recovery on long-term outcomes and characterize the regression of LVH in a large cohort of patients followed up after AVR. Our aims are to improve the understanding of LV remodeling after AVR and to help cardiologists and surgeons refine indications, prognostication, timing, and follow-up in their patients.
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Methods
Patients Figure 1 depicts the flowchart of the study. A total of 6136 consecutive adult patients underwent AVR with or without coronary artery bypass grafting and with or without root or ascending aorta repair or replacement between 1970 and 2012 at the University of Ottawa Heart Institute (Ottawa, ON, Canada). Patients who underwent concomitant mitral surgery were excluded. Of the 6136 patients, 3112 patients had a detailed record of preoperative LV function, and of those 3112 patients, 644 had severe AS or aortic regurgitation (AR) with preoperative LV dysfunction, and 723 were known to have LVH preoperatively. In these patients, we examined the effect of LV function and recovery on long-term clinical outcomes and identified the time course and correlates of LV mass regression, respectively. Severe AS was defined by at least 1 of the following hemodynamic measurements: transaortic valve peak pressure gradient ≥64 mm Hg, transaortic valve mean pressure gradient ≥40 mm Hg, or aortic valve area ≤1.0 cm 2 . 11 If patients had AS with a severity that was equal to or higher than the AR severity, they were classified as having AS. To minimize the potential impact of low-gradient AS, moderate aortic valve disease, or operations primarily for coronary artery disease, patients without severe AS or AR were not included in the clinical outcome analyses; however, patients with moderate AS and AR were included in the analyses of echocardiographic LV mass regression.
LV grades 1, 2, 3, and 4 were defined as ejection fraction ≥50%, 35% to 49%, 20% to 34%, and <20%, respectively. LV function recovery was defined as ≥1 grade echocardiographic improvement from preoperative LV grade during follow-up. Full recovery of LV function was defined as recovery to grade 1 at any time during follow-up.
LV mass was calculated by using M-mode recordings according to the American Society of Echocardiography 12 and was indexed to body surface area. LVH was defined as a LV mass index (LVMI) >116 g/m 2 in men and LVMI >96 g/m 2 in women. LV mass regression was expressed as the percent change in LVMI from baseline, with positive values indicating regression. Maximum LV mass regression corresponded to the most positive value for each patient compared with baseline at any point during follow-up.
The in vivo effective orifice area (EOA) for each prosthesis type and size was obtained from the scientific literature reporting normal prosthesis function. 3, 13 Indexed EOA was calculated by using the patients' body surface area at the time of operation. Prosthesis-patient mismatch (PPM) was defined as an indexed EOA ≤0.85 cm 2 /m 2 .
Operative Techniques
The aortic valve prostheses were implanted in the supra-annular or intraannular position by the use of horizontal mattress sutures of 2-0 polyester with pledgets or single sutures of 2-0 polyester without pledgets, according to model, size, and surgeon preference. Crystalloid cardioplegia was used until June 2005; blood cardioplegia was used thereafter. The implanted valves prostheses are shown in Table I 
Follow-Up
After AVR, patients were annually assessed in a dedicated valve clinic, focusing on the determination of functional status and valverelated complications with ECG, chest x-ray, complete blood count, serum chemistries, and international normalized ratio determinations as applicable. CHF was defined as New York Heart Association (NYHA) class 3 or 4 symptoms of >4 weeks in duration or hospitalization for CHF. 
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As correlates of clinical outcomes, the following interval variables were assessed: age in 10-year increments, LV end-diastolic diameter (LVEDD) in 10-mm increments, LV end-systolic diameter (LVESD) in 10-mm increments, LVMI in 20-g/m 2 increments, and cardiopulmonary bypass (CPB) duration in 30-minute increments. In addition, the following categorical variables were assessed: sex, NYHA class 3 or 4, preoperative LV grade 3 or 4, history of thromboembolism, preoperative pulmonary congestion, low preoperative transaortic valve mean pressure gradient (defined as <40 mm Hg), low preoperative transaortic valve peak pressure gradient (<64 mm Hg), PPM, and concomitant coronary artery bypass grafting. After univariable log-rank testing, only variables with values of P<0.20 were considered in Cox proportional hazards analyses, in which stepwise forward selection techniques used values of P<0.20 for entry and P≥0.20 for removal. For the assessment of correlates of LV recovery, a competing-risk regression was used to account for competing death hazards according to the methods of Fine and Gray, 14 and cumulative incidences and confidence intervals (CIs) for the distinct end point of LV recovery were estimated by the use of a delta method. 15 In addition to the deaths in the patients followed up with echocardiography, we included, as a competing risk for LV recovery, patients who died between 30 days and 2 years after the operation and who had not received any followup echocardiograms. LVEDD ≤70, ≤65, ≤60, ≤55, and ≤50 mm and LVESD ≤60, ≤55, ≤50, ≤45, and ≤40 mm were assessed as categorical variables. We chose the thresholds of LVEDD and LVESD with the smallest P value on univariable analyses and added them to the multivariable analyses. The effects of LV recovery on clinical outcomes were examined by use of an extended Cox model in which LV recovery was treated as a time-dependent covariate.
Univariable and multivariable linear regression analyses were used to identify independent correlates of maximum LV mass regression. In addition to the aforementioned variables, severity of AS and severity of AR were used as ordinal variables, and age (years), LVEDD (mm), LVESD (mm), preoperative LVMI (g/m 2 ), and CPB duration (minutes) were assessed as continuous variables.
Results

Patient Characteristics
The mean age of the patients was 67.8±13.4 years (range, 18-96 years) at the time of AVR, and 66.9% were male. The characteristics of all the 3112 patients are shown in Table II in the online-only Data Supplement. Patients in the AS group were older compared with those in the AR group (70.5±11.6 versus 52.7±14.8 years; P<0.001). Table 1 shows the perioperative patient characteristics by groups defined according to valve lesion and LV function. In patients with severe AS, preoperative LV dysfunction was associated with male sex, older age, concomitant coronary artery bypass grafting, bigger implanted valves, and higher indexed EOA postoperatively.
Clinical Outcomes According to Preoperative LV Function
A total of 60 patients (1.9%) died during the first month after AVR; 91 patients died 1 month to 1 year postoperatively; and another 400 patients died over the follow-up period. Estimated survival at 1, 5, 10, 15, and 20 years after operation was 94.8±0.4%, 85.8±0.8%, 70.5±1.4%, 55.9±2.0%, and 43.9±2.5%. CHF was identified in 193 patients over the follow-up period. Estimated survival at 15 years for patients with preoperative LV grades 1, 2, 3, and 4 was 62.3±2.4%, 47.6±4.5%, 41.2±5.8%, and 36.9±8.4%, respectively (P<0.001; Figure IA in the online-only Data Supplement). Overall, significant differences in survival according to preoperative LV function were seen in patients with severe AS (P<0.001), but differences were not statistically significant in patients with severe AR (P=0.055; Figure IB 
Severe AR Group
The independent correlates of the composite outcome of all-cause mortality or CHF were older age (HR, 1.7 per 10-year increase; 95% CI, 1.2-2.4; P=0.002) in the normal LV function group and older age (HR, 1.8 per 10-year increase; 95% CI, 1.1-3.2; P=0.027) and higher LVMI (HR, 1.3 per 20-g/m 2 increase; 95% CI, 1.1-1.6; P=0.003) in the LV dysfunction group (Table 3) .
Associations Between Clinical Outcomes and LV Recovery
Of the 369 LV dysfunction patients followed up with echocardiograms, 308 experienced LV function recovery after AVR. Twentyfour patients died between the perioperative period (defined as 30 days) and 2 years after AVR without receiving any echocardiograms. After the competing risk of death was accounted for, the cumulative incidences of LV recovery by at least 1 grade at 5, 10, and 15 years postoperatively were 68.6±2.4%, 81.4±1.9%, and 86.2±1.5%, respectively. Postoperative LV recovery took less time and occurred more frequently in the severe AS group than in the severe AR group (83.7±1.7% versus 68.7±6.0% at 10 years; subhazard ratio of AR versus AS for LV nonrecovery, 1.6; 95% CI, 1.2-2.0; P=0.001; Figure 2) . A preoperative LVEDD ≤55 mm was an independent correlate of LV recovery by at least 1 grade in patients with severe AS and LV dysfunction (subhazard ratio, 1.5; 95% CI, 1.1-1.9; P=0.008). In patients with severe AR and preoperative LV dysfunction, a preoperative LVESD ≤60 mm trended to be associated with recovery by at least 1 grade (subhazard ratio, 2.6; 95% CI, 0.9-7.2; P=0.07). The time course toward full LV recovery (ie, to grade 1) is depicted in Figure II in the online-only Data Supplement.
LV recovery strongly correlated with a lower hazard of the mortality and CHF composite outcome (HR, 0.5; 95% CI, Figure 3 ). For AS, 88.6% of patients experienced LV mass regression by a maximum LV of 25.8±20.9%, occurring at a mean of 24.8±38.8 months. For AR, 92.6% of patients experienced LV mass regression by 34.7±22.5%, occurring at a mean of 59.0±71.0 months (P<0.001 versus AS). Tables 4 and 5 show independent correlates of maximum LV mass regression according to the aortic valve lesion. In AS patients, independent correlates of maximum LV mass regression were higher preoperative LVMI (0.24±0.03% per 1-g/m 2 increase; P<0.001) and smaller LVESD (−0.44±0.13% per 1-mm increase; P=0.001). In patients with AR, independent correlates were higher preoperative LVMI (0.13±0.04% per 1-g/ m 2 increase; P=0.001) and NYHA class 1 or 2 (11.18±4.57%; P=0.017).
Discussion
This study reports, to the best of our knowledge, the largest series of patients followed up for clinical outcomes, recovery of LV function, and LV mass regression in the late chronic phase after AVR. We found that ≈65% of patients with severe aortic valve lesions and LV dysfunction experience recovery of at least 1 LV grade by 5 years after AVR and that LV recovery correlates with better survival and freedom from CHF. We found an independent association between preoperative LV size and postoperative LV recovery. Preoperative LVEDD ≤55 mm in AS patients was associated with more frequent LV recovery. We showed that, in AS and AR patients with preoperative LVH, LV mass regression occurs in a large proportion of patients, namely 88.6% and 92.6%, respectively, and that its completion takes longer in AR than in AS patients, with a mean maximum regression of 25.8% occurring at a mean of 24.8 months in AS patients and of 34.7% occurring at 59.0 months in AR patients. Finally, we also found that patients with AR and LVH referred for AVR at a less symptomatic stage experience more complete LV mass regression.
Preoperative low transaortic valve pressure gradient was associated with worse clinical outcomes in patients with severe AS and LV dysfunction. Furthermore, PPM was associated with worse survival or freedom from CHF among severe AS patients with LV dysfunction and in those <70 years of age regardless of LV function. Notably, mean indexed EOA was larger in patients with LV dysfunction than in those with normal LV function. This suggests that surgeons may already have been implanting larger valves in patients with LV dysfunction or that LV dysfunction may lead to LV outflow tract and aortic root dilatation, as a previous study suggested. 16 LV function recovery led to better long-term clinical outcomes, which is consistent with smaller, prior studies. For instance, Morris et al 6 reported that the 72% of patients with improved ejection fraction postoperatively had better survival after AVR than the 28% patients whose ejection fraction did not improve. Vaquette et al 17 reported that 55 patients with early LV recovery of >10 ejection fraction units had better AS indicates aortic stenosis; AVMG, transaortic valve mean pressure gradient; CPB, cardiopulmonary bypass; CHF, congestive heart failure; CI, confidence interval; EOA, effective orifice area; HR, hazard ratio; LV, left ventricular; NYHA, New York Heart Association; and PPM, prosthesis-patient mismatch.
*Nonsignificant variables were included in final model because the P value was <0.20. long-term survival than the 68 patients with LV recovery ≤10 ejection fraction units. In many instances, nonrecovery of LV function may be attributable to the LV myocardium having developed myocardial fibrosis with diastolic dysfunction. Magnetic resonance imaging can detect the amount of fibrosis in the myocardium, which may correlate with clinical outcomes. 18, 19 However, further research is needed on this topic for magnetic resonance imaging to be validated and widely performed.
Clinical Implications
Many groups are already taking measures to avoid PPM in patients with severe AS and impaired LV, 4, 20, 21 and we should also consider doing so in AS patients with normal LV function who are <70 years of age. Low transaortic valve pressure gradients and large LVEDD may translate into irreversible myocardial changes. In such patients, clinicians should be careful; magnetic resonance imaging and dobutamine stress echocardiography may be useful. Our data support surgery before the development of advanced NYHA symptoms in patients with AR and LVH. Maximum LV mass regression after AVR takes more time in patients with AR than in patients with AS, that is, >4 and 2 years, respectively. Because NYHA class, aortic valve pressure gradient, ejection fraction, LV diameter, and LV mass are very common parameters used all over the world, the findings of the present study have wide use.
Limitations
This is a single-center, retrospective study. There is a possibility of bias in patient selection because data used for statistical analyses come from only ≈50% of AVR cases performed during the study period. Echocardiograms were not always performed every year and may have affected the observed time course of LV recovery and LV mass regression. CPB duration is difficult to interpret accurately as a correlate because it includes factors such as surgeon skills and the type of concomitant surgery, including coronary artery bypass grafting or aortic surgery. Consequently, the conclusions may not necessarily be generalizable and could have been subject to uncontrolled and unknown patient characteristics or surgical factors acting as confounders. Another limitation is the definition of LV recovery based on prospectively collected LV grade information rather than ejection fraction values per se, thereby representing ordinal rather than true interval change. Although LV recovery was used as a time-dependent covariate in the analyses of correlates of clinical outcomes, details of subsequent LV deterioration after LV recovery, if any, are not reported in this article. Finally, although this study provides new insights into the outcomes of AVR in terms of mortality, morbidity, and LV remodeling/mass regression in patients with preoperative LV dysfunction and LVH, more research, including causes of death, is needed to further our mechanistic understanding of the impact of LV dysfunction and LVH on long-term outcomes after AVR. 
Conclusions
Most patients with severe aortic valve lesions and LV dysfunction experience LV recovery after AVR, and LV recovery correlates with better clinical outcomes. Maximum regression of preoperative LVH takes 2 years in patients with AS and >4 years in patients with AR. In patients with severe AS, LV recovery is less likely to occur when preoperative LVEDD is >55 mm. PPM (indexed EOA ≤0.85 cm 2 /m 2 ) and transaortic valve mean pressure gradient <40 mm Hg are also associated with worse clinical outcomes in patients with severe AS and LV dysfunction. Patients with AR and LVH may benefit from being operated on at an early stage, before the development of advanced symptoms. Taken together, these findings suggest that AVR should be considered before transaortic valve gradients decrease, before advanced NYHA class symptoms occur, and before LV diameters increase. Moreover, this study confirms that PPM should also be avoided in younger patients regardless of LV function to optimize short-and long-term clinical outcomes.
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